Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W; National Steering Committees. Odin P, et al. Among authors: slevin jt. Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. doi: 10.1016/j.parkreldis.2015.07.020. Epub 2015 Jul 23. Parkinsonism Relat Disord. 2015. PMID: 26233582 Free article. Review.
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Olanow CW, et al. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Lancet Neurol. 2014. PMID: 24361112 Free PMC article. Clinical Trial.
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J. Lang AE, et al. Among authors: slevin jt. Mov Disord. 2016 Apr;31(4):538-46. doi: 10.1002/mds.26485. Epub 2015 Dec 23. Mov Disord. 2016. PMID: 26695437 Free PMC article.
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH. Moonen AJ, et al. Parkinsonism Relat Disord. 2014 Jun;20(6):644-6. doi: 10.1016/j.parkreldis.2014.02.025. Epub 2014 Mar 18. Parkinsonism Relat Disord. 2014. PMID: 24679737
Trichloroethylene and Parkinson disease.
Zaheer F, Slevin JT. Zaheer F, et al. Among authors: slevin jt. Neurol Clin. 2011 Aug;29(3):657-65. doi: 10.1016/j.ncl.2011.05.001. Epub 2011 Jul 7. Neurol Clin. 2011. PMID: 21803216 Review.
Drug treatment strategies for depression in Parkinson disease.
Ryan M, Eatmon CV, Slevin JT. Ryan M, et al. Among authors: slevin jt. Expert Opin Pharmacother. 2019 Aug;20(11):1351-1363. doi: 10.1080/14656566.2019.1612877. Epub 2019 May 23. Expert Opin Pharmacother. 2019. PMID: 31120798 Review.
98 results